- Datum02.05.2024
- Uhrzeit14:00 - 15:00 Uhr
- Veranstalter
XTB
Jens Klatt
Moderator
Amphastar Pharmaceuticals Inc. Registered Shares DL -,0001
Verkaufen
Kaufen
stock3 TerminalDu willst selbst ins Charting einsteigen?
Nutze das Charting-Widget auf dem stock3 Terminal für Deine eigene Analyse. Mehr Features. Mehr Werkzeuge. Mehr stock3.
Chart im Terminal öffnen
Amphastar Pharmaceuticals Inc. Registered Shares DL -,0001 Kurse
| Name | Kurs | +/- (%) | +/- (abs) | Vortag | Zeit | Aktionen |
|---|---|---|---|---|---|---|
| L&S | VK | |||||
| Tradegate | VK | |||||
| Stuttgart | VK |
Passende Produkte
| WKN | Long/Short | KO | Hebel | Laufzeit | Bid | Ask |
|---|
Keine Ergebnisse gefunden
Wertentwicklung (Nasdaq)
1,92 %
Intraday
3,06 %
1 Woche
-0,57 %
1 Monat
-31,96 %
Seit Jahresbeginn
13,88 %
1 Jahr
141,84 %
3 Jahre
92,23 %
5 Jahre
Wikifolio
Passender Service zu Amphastar Pharmaceuticals Inc. Registered Shares DL -,0001
Webinar zu Amphastar Pharmaceuticals Inc. Registered Shares DL -,0001
Kursinformationen (Nasdaq)
- Tagestief / Hoch ($)-
- 52W-Tief / Hoch ($)35,930-67,660
- Jahrestief / Hoch ($)38,430-65,925
- Schlusskurs (Vortag)
- Eröffnungskurs
- Volumen Intraday
Wichtigste Eigenschaften
Dividenden von Amphastar Pharmaceuticals Inc. Registered Shares DL -,0001
Keine Dividenden verfügbar
Termine von Amphastar Pharmaceuticals Inc. Registered Shares DL -,0001
- Mai8Amphastar Pharmaceuticals Inc. Registered Shares DL -,0001Q1 2024 Earnings Release
- Aug5Amphastar Pharmaceuticals Inc. Registered Shares DL -,0001Q2 2024 Earnings Release
- Nov4Amphastar Pharmaceuticals Inc. Registered Shares DL -,0001Q3 2024 Earnings Release
Beschreibung
Amphastar Pharmaceuticals Inc is a biopharmaceutical company that focuses on developing, manufacturing, marketing, and selling technically challenging generic and proprietary injectable, inhalation, and intranasal products. Additionally, the company sells insulin API products. The company's finished products are used in hospital or urgent care clinical settings and are contracted and distributed through group purchasing organizations and drug wholesalers. The company has two reportable segments finished pharmaceutical products and API products. Geographically the business presence of the firm is seen in the United States, China and France of which the U.S. accounts for the majority of the revenue.
